Physician profile
Don Pham
NPI 1053631580
$11,045.38
in general payments reported to CMS, 2019-2025
24 companies · $963 in 2025
The $963 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $1,100 · 2021: $985 · 2022: $4,615 · 2023: $1,538 · 2024: $548 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $3,994.57 | 2020-2022 | |
| Abbott Laboratories | $2,888.83 | 2019-2024 | Aveir, Advisor, Gallant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $674.82 | 2019-2025 | Lifevest |
| Medtronic, INC. | $603.39 | 2021-2024 | Corevalve Evolut R, Turbohawk |
| Cvrx, INC. | $534.54 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $444.69 | 2019-2025 | |
| Abiomed | $261.67 | 2021-2023 | Impella |
| Boston Scientific Corporation | $184.20 | 2020-2022 | |
| Shockwave Medical, INC | $182.14 | 2025 | |
| Tactile Systems Technology INC | $179.24 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Janssen Pharmaceuticals, INC | $171.64 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $141.22 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $118.01 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $117.04 | 2022-2025 | |
| Philips North America LLC | $111.98 | 2024 | (Bh4) Igt Devices Undivided |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $100.56 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $72.05 | 2020-2025 | Lokelma |
| Esperion Therapeutics, INC. | $57.35 | 2021 | |
| Novo Nordisk INC | $53.27 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.19 | 2019-2022 | |
| Chiesi USA, INC. | $40.99 | 2019 | |
| Bridgebio Pharma, INC. | $25.83 | 2025 | Attruby |
| Lilly USA, LLC | $18.67 | 2021 | |
| Teleflex LLC | $16.49 | 2023 | Turnpike |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.